{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "We randomized 30 patients undergoing primary TKA"
      },
      "Participants": {
        "score": 1,
        "evidence": "30 patients undergoing primary TKA"
      },
      "Intervention": {
        "score": 2,
        "evidence": "250 or 500 mg vancomycin via IORA or 1 g via systemic administration"
      },
      "Objective": {
        "score": 1,
        "evidence": "We assessed whether low-dose IORA vancomycin can achieve tissue concentrations equal or superior to those of systemic administration in TKA"
      },
      "Method_Outcome": {
        "score": 1,
        "evidence": "antibiotic concentrations measured"
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "We randomized 30 patients"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "We randomized 30 patients"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "The overall mean tissue concentration of vancomycin in subcutaneous fat was 14 \u03bcg/g in the 250-mg IORA group, 44 \u03bcg/g in the 500-mg IORA group, and 3.2 \u03bcg/g in the systemic group."
      },
      "Harms": {
        "score": 1,
        "evidence": "One patient in the systemic group developed red man syndrome during infusion."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 11,
    "max_score": 25
  },
  "model": "gpt-4o"
}